- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04258306
Pilot Study to Evaluate the Plasma Profile of Revifast
Randomized, Single-blind, Cross-over Pilot Study to Evaluate the Plasma Profile of Resveratrol Following an Oral Administration of Either Revifast® (Resveratrol From Polygonum Cuspidatum Extract Siebold & Zucc - Root Supported on Magnesium Hydration With a Weight Titer of Min. 30% Resveratrol) and Unsupported Pure Resveratrol
The purpose of this study is to evaluate in 6 subjects aged between 18 and 60 years the peak blood (plasma profile) of two formulations, indistinguishable from each other, containing:
A) 180 mg natural Resveratrol (Polygonum cuspidatum 98%) B) 180 mg of Revifast® (resveratrol from supported on Magnesium hydroxide).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be randomized, controlled, single blind, cross-over, using the two granular compounds in capsules A and B, indistinguishable from each other, dissolved in aqueous solution and administered orally. either A:180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.
B) 180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold & Zucc. Root supported on Magnesium hydroxide).
Cross-over refers to a type of clinical study in which each individual receives each of the treatments consecutively.
PHASE I: The subjects will be given, on the first day, in the morning on an empty stomach, a solution of content A or B obtained by dissolving the contents of the capsule in water which will then be taken orally. Samples of 2 ml of venous blood in a tube containing EDTA will be taken from a vein in the arm using a cannula at 0 min (fasting before administration), 15 min, 30 min, 60 min, 90 min, 120 min, 180 min .
WASH-OUT: 1 day. PHASE II: On the third day, the person who had taken the solution A will take the solution B, and vice versa, with the same methods and times described above.
The study will have a total duration of 6 weeks divided as follows:
- Pre-monitoring phase, enrollment of subjects, random assignment in two arms 1 and 2 each consisting of 3 subjects and signature of the informative consent regarding the adhesion to the study protocol (1 week);
- 1 week for taking samples and storing them for routine chemical / biochemical analyzes carried out at the Crabion S.R.L. accredited center based in Corciano in via Amilcare Ponchielli 8 (on the first day, arm 1 will start treatment with solution A; on the second day, this arm will wash-out and arm 2 will start treatment with solution A; on third day on arm 1 will start the treatment with solution B and arm 2 will wash-out; on the fourth day arm 2 will carry out the treatment with solution B; once the routine analyzes have been carried out, on the fifth day the frozen samples will be sent to the Department of chemistry, biology and biotechnology of the University of Perugia for subsequent extraroutine analyzes).
- 2 weeks for carrying out the pharmacological and metabolomic analyzes of extraroutins performed at the Department of chemistry, biology and biotechnology of the University of Perugia;
- 2 weeks for carrying out statistical tests and processing the data obtained.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
PG
-
Perugia, PG, Italy, 06131
- Deparment of Chemistry, Biology and Biotechnology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects naive to taking resveratrol, willing and able to understand and sign an informed consent;
- Normal blood and chemical tests: blood count, lipid structure, kidney and liver function, inflammatory structure (Tnfα, reactive protein C, ESR), glycemic profile (Fasting blood glucose, HbA1C, insulinemia, Homa Index).
Exclusion Criteria:
- Chronic pathologies (chronic renal failure, chronic hepatocellular insufficiency, autoimmune diseases, chronic inflammatory bowel diseases, diabetes mellitus, end-stage neoplasms, symptomatic chronic ischemic heart disease);
- severe arterial hypertension;
- High degree hypercholesterolaemia;
- Up to two previous days' intake of red wine not exceeding 2 glasses / day for men and 1 glass / day for women;
- Up to two previous days intake of foods containing resveratrol (red grapes, blueberries, dried fruit);
- Age <18 years;
- Poor compliance;
- Taking dietary supplements containing antioxidants;
- Untreated hypothyroidism;
- Pregnant and breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Resveratrol
180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.
|
resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
Other Names:
|
Experimental: REVIFAST
180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold & Zucc.
Root supported on Magnesium hydroxide).
|
Revifast® is based on natural resveratrol supported on Magnesium hydroxide.
Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the plasma concentration (micromolar concentration) of free resveratrol after administration of a tablet containing 150mg of resveratrol in either the Resv@MDH form or pure resveratrol dissolved in water.
Time Frame: 2 days
|
Analysis of the peak plasmatic profile of resveratrol in venous blood samples at specific time intervals and after administration of a tablet dissolved in water of two different formulations based on resveratrol.
Timing of blood samples: (fasting before administration), 15 min, 30 min, 60 min, 90 min, 120 min, 180 min after oral administration.
Samples of blood will be analyzed for pharmacological and metabolomic analysis of resveratrol and evaluate the concentration of resveratrol (micro molar) using a mass spectrometer.
|
2 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RVF01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nutrient; Excess
-
University of OxfordRecruitingNAFLD | Nutrient; ExcessUnited Kingdom
-
Boston Heart DiagnosticsDavid M. Katz, M.D.UnknownLifestyle-related Condition | Nutrient; Excess
-
Clinical Evaluation Research Unit at Kingston General...UnknownCardiovascular Diseases | Aging | Nutrient; ExcessCanada
-
Chung Shan Medical UniversityCompletedObesity | Diet Modification | Nutrient; ExcessTaiwan
-
Duzce UniversityRecruitingCrohn Disease | Nutrient; Excess | Remission/RegressionTurkey
-
University of MiamiNational Institute of Nursing Research (NINR)Active, not recruitingPhysical Activity | Overweight and Obesity | Adiposity | Nutrient; ExcessUnited States
-
University of Illinois at Urbana-ChampaignUniversity of Houston; University of Puerto Rico; Iowa State University; California...UnknownObesity | Childhood Obesity | Nutrient; Excess | Community Health EducationUnited States, Puerto Rico
-
Shape Divine Center SRLSmartepigenetX SRL; Advanced Nutrigenomics LLCRecruiting
-
University of California, San FranciscoUniversity of Colorado, Denver; University of California, Davis; Post Graduate...CompletedNutrient DeficiencyIndia
-
The University of Texas Medical Branch, GalvestonNational Institute on Aging (NIA)Completed
Clinical Trials on pure resveratrol
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.; Diabetes FondsCompleted
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.Unknown
-
Maastricht University Medical CenterCompleted
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.; The Netherlands Asthma FoundationCompletedPulmonary Disease, Chronic ObstructiveNetherlands
-
Andrews Research & Education FoundationEmCyte Corporation; BioSciences Research Associates, IncCompletedKnee OsteoarthritisUnited States
-
National Taiwan University HospitalNational Science and Technology Council, TaiwanNot yet recruitingChronic StrokeTaiwan
-
BioSig Technologies, Inc.Completed
-
Vitti Labs, LLCRecruitingRespiratory Distress Syndrome | COVID-19 Acute Respiratory Distress SyndromeUnited States
-
The David Hide Asthma & Allergy Research CentreIsle of Wight NHS TrustCompleted
-
Ministry of Health, MalaysiaCompleted